Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Cancer Lett
    November 2026
  1. PEI X, Lv M, Zhao X, Liu Z, et al
    Rapid manufactured CAR-T cells enriched for CD45RA-negative T cells exhibit superior persistence compared to conventional CAR-T therapy.
    Cancer Lett. 2026;661:218865.
    >> Share

    October 2026
  2. JIN Y, An ZY, Zhao P, Fu HX, et al
    GAMMA: A genetic-clinical prognostic model for risk stratification in patients with relapsed/refractory acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation.
    Cancer Lett. 2026 Oct 8:218883. doi: 10.1016/j.canlet.2026.218883.
    >> Share

  3. BENETTON M, Da Ros A, Peloso A, Longo G, et al
    Reactive oxygen species define leukemia stem cell identity in pediatric acute myeloid leukemia.
    Cancer Lett. 2026 Oct 4:218866. doi: 10.1016/j.canlet.2026.218866.
    >> Share

    August 2026
  4. WANG L, Li Y, Xie W, Li R, et al
    The Fbxw11-Dpysl2 ubiquitin axis restrains the progression of acute myeloid leukemia.
    Cancer Lett. 2026 Aug 12:218782. doi: 10.1016/j.canlet.2026.218782.
    >> Share

    July 2026
  5. SUN Y, Liu J, Chen J, Xuan L, et al
    Impact of Concurrent Genetic Alterations on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Cancer Lett. 2026 Jul 10:218724. doi: 10.1016/j.canlet.2026.218724.
    >> Share

  6. MA R, Zhang J, Zhang MX, Li Y, et al
    Survival benefit of allogeneic HSCT in CMML patients during the molecular stratification era.
    Cancer Lett. 2026;649:218489.
    >> Share

    May 2026
  7. WANG JD, Liao CJ, Lei XX, Peng ZZ, et al
    NPM1 mutation promotes creatine anabolism by FTO-dependent m(6)A demethylation to drive macrophage M2 polarization in acute myeloid leukemia.
    Cancer Lett. 2026 May 29:218637. doi: 10.1016/j.canlet.2026.218637.
    >> Share

  8. SHAO G, Pan H, Zhu J, Zhuo N, et al
    Repurposing the Neurokinin-1 Receptor Antagonist Aprepitant to Eradicate Relapsed/Refractory Acute Lymphoblastic Leukemia via Mitochondria-Driven Necroptosis.
    Cancer Lett. 2026 May 24:218621. doi: 10.1016/j.canlet.2026.218621.
    >> Share

    February 2026
  9. PHILIPPE C, Jaud M, Da Cunha C, Van Den Berghe L, et al
    The endoplasmic reticulum stress-regulated XBP1s transcription factor drives a negative feedback loop on FLT3 expression in leukemia cells.
    Cancer Lett. 2026 Feb 10:218310. doi: 10.1016/j.canlet.2026.218310.
    >> Share

    January 2026
  10. CAI J, Liang CH, Han LP, Jiang HY, et al
    Dysregulation of the ALDH1A3/PML-RARalpha axis promotes the progression of acute promyelocytic leukemia.
    Cancer Lett. 2026 Jan 22:218280. doi: 10.1016/j.canlet.2026.218280.
    >> Share

    December 2025
  11. ZHU K, Zhang H, Li G, Zong S, et al
    lncDDR suppresses drug resistance by regulating DNA damage repair through ILF2-YB1 in T-cell acute lymphoblastic leukemia.
    Cancer Lett. 2025;639:218210.
    >> Share

    November 2025
  12. SU Y, Xu X, Yang G, Chen B, et al
    Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies.
    Cancer Lett. 2025;633:218014.
    >> Share

  13. JIANG Y, Liu F, Yang Y, Huang J, et al
    Bone marrow-based highly sensitive proteomics profiling reveals valuable biomarkers for pediatric B-cell acute lymphoblastic leukemia.
    Cancer Lett. 2025 Nov 11:218130. doi: 10.1016/j.canlet.2025.218130.
    >> Share

    September 2025
  14. HE SJ, Shu LP, Zhou ZW, Yang T, et al
    Corrigendum to "Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells" [Cancer. Lett. (382) 2016-11-28; 382(2):215-230].
    Cancer Lett. 2025 Sep 27:218039. doi: 10.1016/j.canlet.2025.218039.
    >> Share

  15. MILLS TS, Arnone M, Gorsch E, Poeschel S, et al
    MRC2 expression modulates metabolism in acute myeloid leukemia stem cells.
    Cancer Lett. 2025 Sep 26:218068. doi: 10.1016/j.canlet.2025.218068.
    >> Share

  16. MA W, Jamieson C
    Developmental checkpoint targeting: Pre-TCR immunotherapy in leukemia and beyond.
    Cancer Lett. 2025 Sep 26:218063. doi: 10.1016/j.canlet.2025.218063.
    >> Share

  17. CAI M, Xia Z, Shao C, Du W, et al
    P2RY8::TSC22D3 is a novel fusion associated with chemoresistance in leukemia by activating PI3K-AKT pathway.
    Cancer Lett. 2025;633:218040.
    >> Share

  18. POTTIER A, Park S, Lee Y, Liccardo F, et al
    TP53-Agnostic Lethality through Combined Pan-HDAC and CDK Inhibition in Acute Myeloid Leukemia.
    Cancer Lett. 2025 Sep 1:218011. doi: 10.1016/j.canlet.2025.218011.
    >> Share

    July 2025
  19. HU X, Hu T, Cao S, Zheng L, et al
    The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML.
    Cancer Lett. 2025 Jul 31:217963. doi: 10.1016/j.canlet.2025.217963.
    >> Share

    June 2025
  20. LU H, Wang H, Wang Q, Huang D, et al
    Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq.
    Cancer Lett. 2025 Jun 5:217853. doi: 10.1016/j.canlet.2025.217853.
    >> Share

    May 2025
  21. XIANG G, Zhu P, Zhang L, Yu S, et al
    Effective leukemia-to-granulocyte induction by a cocktail of RUNX1, SPI1 and CEBPE.
    Cancer Lett. 2025;626:217820.
    >> Share

  22. HU LJ, Li CY, Xing T, Wang Y, et al
    N-acetyl-L-cysteine promoted hematopoietic recovery in patients with acute myeloid leukemia after complete remission--A pilot study.
    Cancer Lett. 2025 May 20:217812. doi: 10.1016/j.canlet.2025.217812.
    >> Share

    April 2025
  23. MA XH, Gao MG, Cheng RQ, Qin YZ, et al
    The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression.
    Cancer Lett. 2025;615:217547.
    >> Share

  24. LIU Y, Tu Y, Yan Z, Xiao J, et al
    CAR T-Cell Therapy in Chronic Myeloid Leukemia Patients with Lymphoid Blast Crisis: A Multicenter Clinical Analysis.
    Cancer Lett. 2025 Apr 1:217688. doi: 10.1016/j.canlet.2025.217688.
    >> Share

    March 2025
  25. WANG Y, Liu W, Gu Z, Chang Y, et al
    Allogeneic versus autologous hematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: a real-world multicenter analysis in China.
    Cancer Lett. 2025 Mar 21:217664. doi: 10.1016/j.canlet.2025.217664.
    >> Share

    February 2025
  26. CHEN DW, Schrey JM, Wafula EK, Fan JM, et al
    Leukemia confers a durable imprint on healthy hematopoietic stem and progenitor cells.
    Cancer Lett. 2025;616:217590.
    >> Share

  27. LIU C, Liu G, Zhou F, Chen L, et al
    EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis.
    Cancer Lett. 2025;614:217556.
    >> Share

    January 2025
  28. WEISS S, Zdarsky B, Witalisz-Siepracka A, Edtmayer S, et al
    Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia.
    Cancer Lett. 2025;613:217501.
    >> Share

  29. LI M, Li Y, Qu Q, Wang C, et al
    Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cancer Lett. 2025 Jan 11:217460. doi: 10.1016/j.canlet.2025.217460.
    >> Share

  30. PEI HZ, Guo Y, Zhao Y, Zhang D, et al
    FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia.
    Cancer Lett. 2025;611:217446.
    >> Share

  31. HINDES MT, McElligott AM, Best OG, Ward MP, et al
    Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.
    Cancer Lett. 2025 Jan 2:217441. doi: 10.1016/j.canlet.2025.217441.
    >> Share

    December 2024
  32. WANG J, Ma W, Huang J, Qiu G, et al
    Corrigendum to "HIF-2alpha 1 inhibition disrupts leukemia stem cell metabolism and impairs vascular microenvironment to enhance chronic myeloid leukemia treatment" [Cancer lett. 597 (2024) 217060].
    Cancer Lett. 2024 Dec 31:217435. doi: 10.1016/j.canlet.2024.217435.
    >> Share

  33. JIN P, Shen J, Zhao M, Yu J, et al
    Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy.
    Cancer Lett. 2024 Dec 24:217427. doi: 10.1016/j.canlet.2024.217427.
    >> Share

  34. VAN TRIMPONT M, Schalk AM, Hofkens K, Peeters E, et al
    A human-like glutaminase-free asparaginase is highly efficacious in ASNS(low) leukemia and solid cancer mouse xenograft models.
    Cancer Lett. 2024 Dec 19:217404. doi: 10.1016/j.canlet.2024.217404.
    >> Share

    November 2024
  35. WANG Y, Chang YJ, Chen J, Han M, et al
    Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update.
    Cancer Lett. 2024;605:217264.
    >> Share

  36. HLOZKOVA K, Vasylkivska M, Boufersaoui A, Marzullo B, et al
    Rewired glutamate metabolism diminishes cytostatic action of L-asparaginase.
    Cancer Lett. 2024;605:217242.
    >> Share

    October 2024
  37. WANG ZK, Zhang ZW, Lyu ZS, Xing T, et al
    Inhibition of TGF-beta signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients.
    Cancer Lett. 2024;605:217290.
    >> Share

    August 2024
  38. WANG YQ, Ren Y, Gale RP, Niu LT, et al
    Sphingosine-1 phosphate receptor 1 (S1PR1) expression maintains stemness of acute myeloid leukemia stem cells.
    Cancer Lett. 2024 Aug 5:217158. doi: 10.1016/j.canlet.2024.217158.
    >> Share

    July 2024
  39. LIU T, Gu L, Mui A, Wu Z, et al
    An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues.
    Cancer Lett. 2024 Jul 23:217126. doi: 10.1016/j.canlet.2024.217126.
    >> Share

  40. LIU Y, Zheng L, Li Y, Ma L, et al
    Neratinib impairs function of m6A recognition on AML1-ETO pre-mRNA and induces differentiation of t (8;21) AML cells by targeting HNRNPA3.
    Cancer Lett. 2024;594:216980.
    >> Share

  41. YAN N, Wang ZL, Wang XJ, Gale RP, et al
    Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Cancer Lett. 2024;598:217104.
    >> Share

  42. YAO M, Jiang X, Xiao F, Lv X, et al
    Targeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance.
    Cancer Lett. 2024;593:216949.
    >> Share

    June 2024
  43. WANG J, Ma W, Huang J, Qiu G, et al
    HIF-2alpha Inhibition Disrupts Leukemia Stem Cell Metabolism and Impairs Vascular Microenvironment to Enhance Chronic Myeloid Leukemia Treatment.
    Cancer Lett. 2024 Jun 14:217060. doi: 10.1016/j.canlet.2024.217060.
    >> Share

  44. YUAN J, Zhang J, Zhao B, Liu F, et al
    Single-cell transcriptomic analysis of the immune microenvironment in pediatric acute leukemia.
    Cancer Lett. 2024 Jun 4:217018. doi: 10.1016/j.canlet.2024.217018.
    >> Share

    May 2024
  45. XU M, Li S
    The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
    Cancer Lett. 2024;593:216969.
    >> Share

  46. WANG D, He J, Liu S, Zhang H, et al
    Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
    Cancer Lett. 2024 May 17:216970. doi: 10.1016/j.canlet.2024.216970.
    >> Share

  47. TAN Y, Xin L, Wang Q, Xu R, et al
    FLT3-Selective PROTAC: Enhanced Safety and Increased Synergy with Venetoclax in FLT3-ITD Mutated Acute Myeloid Leukemia.
    Cancer Lett. 2024 May 3:216933. doi: 10.1016/j.canlet.2024.216933.
    >> Share

    April 2024
  48. ZHAO Y, Chen W, Yu J, Pei S, et al
    TP53 in MDS and AML: Biological and clinical advances.
    Cancer Lett. 2024;588:216767.
    >> Share

  49. SUN H, Xie Y, Wu X, Hu W, et al
    circRNAs as prognostic markers in pediatric acute myeloid leukemia.
    Cancer Lett. 2024;591:216880.
    >> Share

    March 2024
  50. HE Y, Jiang S, Cui Y, Liang J, et al
    Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis.
    Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
    >> Share

    February 2024
  51. CHENG C, Liang S, Yue K, Wu N, et al
    STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vdelta2(+) T cells in acute myeloid leukemia.
    Cancer Lett. 2024 Feb 13:216730. doi: 10.1016/j.canlet.2024.216730.
    >> Share

    January 2024
  52. YANG F, Cui X, Wang H, Zhang D, et al
    Iron overload promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of FOS.
    Cancer Lett. 2024 Jan 17:216652. doi: 10.1016/j.canlet.2024.216652.
    >> Share

    December 2023
  53. JUNG YY, Ahn KS, Shen M
    Unveiling autophagy complexity in leukemia: The molecular landscape and possible interactions with apoptosis and ferroptosis.
    Cancer Lett. 2023 Dec 1:216518. doi: 10.1016/j.canlet.2023.216518.
    >> Share

    September 2023
  54. WEN J, Chen Y, Liao C, Ma X, et al
    Engineered mesenchymal stem cell exosomes loaded with miR-34c-5p selectively promote eradication of acute myeloid leukemia stem cells.
    Cancer Lett. 2023 Sep 26:216407. doi: 10.1016/j.canlet.2023.216407.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016